FDA Support for Treating Opioid Addiction With Medication

By | 2017-12-06T05:03:22+00:00 December 6th, 2017|Brainscience Blogs, Brief Bulletins from the Field|

The FDA plans to convene an expert panel to examine the population-level effects of treating opioid addiction with medication in hopes of gaining wider acceptance of and insurance coverage for those medications. During a late October hearing, FDA Commissioner Scott Gottlieb, MD, told the House Committee on Energy and Commerce [...]

New Buprenorphine Formulation Approved for Medication-Assisted Opioid Treatment

By | 2017-12-05T10:29:35+00:00 December 5th, 2017|Brainscience Blogs, Brief Bulletins from the Field|

The Food and Drug Administration has approved an extended-release, subcutaneous injection formulation of buprenorphine for use in treating moderate to severe opioid use disorder (OUD), the manufacturer of the drug announced recently. The new product, called Sublocade, is a monthly injection intended for use in patients who have already begun [...]

ADHD Redux: Overdiagnosed and Overtreated, or Misdiagnosed and Mistreated?

By | 2017-12-04T09:08:38+00:00 December 4th, 2017|Brainscience Blogs, Brief Bulletins from the Field|

By Michael J. Manos, Kimberly Giuliano, and Eric Geyer The Affordable Care Act of 2010 sought to transform medical care in the United States from procedures to performance, from acute episodes of illness to integrated care across the lifespan, and from inefficient care to efficient and affordable care with measurable outcomes. At [...]

Phase 3 Study of Intepirdine Fails in of Mild to Moderate Alzheimer’s Patients

By | 2017-12-01T16:24:37+00:00 December 1st, 2017|Brainscience Blogs, Brief Bulletins from the Field|

An investigational Alzheimer’s drug intended to potentiate acetylcholine release didn’t pass muster in a global phase 3 study, despite a successful phase 2 trial. Intepirdine on a background of stable-dose donepezil failed to confer any cognitive or functional benefit in patients with mild to moderate Alzheimer’s disease. Intepirdine blocks the 5-hydroxytryptamine [...]

Facebook to Expand Artificial Intelligence to Help Prevent Suicide

By | 2017-11-30T11:29:58+00:00 November 30th, 2017|Brainscience Blogs, Brief Bulletins from the Field|

SAN FRANCISCO (Reuters) - Facebook Inc will expand its pattern recognition software to other countries after successful tests in the U.S. to detect users with suicidal intent, the world's largest social media network said on Monday. Facebook began testing the software in the United States in March, when the company [...]

FDA Approves Vraylar for Schizophrenia in Adults

By | 2017-11-30T11:30:29+00:00 November 30th, 2017|Brainscience Blogs, Brief Bulletins from the Field|

Allergan plc has announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for the maintenance treatment of adults with schizophrenia. Vraylar is also approved in the US in adults for the acute treatment of schizophrenia and acute treatment of [...]

JAMA Issues Advance Directives for Dementia

By | 2017-11-06T17:57:54+00:00 November 6th, 2017|Brainscience Blogs, Brief Bulletins from the Field|

Viewpoint November 6, 2017 Advance Directives for Dementia: Meeting a Unique Challenge By Barak Gaster, Eric B. Larson,  and J. Randall Curtis   In the coming years, an increasing number of people will experience dementia. Worldwide, the number of people living with dementia is projected to increase from 47 million in 2015 to 132 million by [...]

ABSTRACTS, VOLUME 42, NUMBER 1

By | 2009-01-12T19:31:54+00:00 January 12th, 2009|Brainscience Blogs, Brief Bulletins from the Field|

Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press ORIGINAL RESEARCH EVIDENCE-BASED MEDICINEORIGINAL RESEARCH: The Trials and Travails Atypical Antipsychotic Drugs and Diabetes in the US Adverse Event Database Bipolar-I Patient Characteristics PTSD Following Short-Term Paroxetine Treatment Aripiprazole in the Treatment of PTSD Memantine: An [...]

Psychopharmacology Bulletin Newsletter 4

By | 2008-11-24T19:26:09+00:00 November 24th, 2008|Brainscience Blogs, Brief Bulletins from the Field|

• ORIGINAL RESEARCH • EVIDENCE BASED MEDICINE • GENERAL PSYCHIATRY Seroquel Once a Day: A Randomized, Double-Blind, Placebo-Controlled Study— This 6-week, randomized, double-blind study aimed to demonstrate efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia resulting in the efficacy of quetiapine XR [...]

Psychopharmacology Bulletin Newsletter 3

By | 2008-10-20T19:42:08+00:00 October 20th, 2008|Brainscience Blogs, Brief Bulletins from the Field|

  Newsletter No. 3, 2008 www.psychopharmbulletin.com Volume 41 • Number 3 • 2008 Psychopharmacology BULLETIN Newsletter the advance newsletter of Psychopharmacology BULLETIN Summary—Index of This Issue On-Press ORIGINAL RESEARCH EVIDENCE BASED MEDICINE Cocaine is a Major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia abstract ~ Objective: To assess [...]